Department of Internal Medicine III, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Haematologica. 2011 Dec;96(12):1783-91. doi: 10.3324/haematol.2011.046888. Epub 2011 Aug 31.
MicroRNAs are regulators of gene expression, which act mainly by decreasing mRNA levels of their multiple targets. Deregulated microRNA expression has been shown for acute myeloid leukemia, a disease also characterized by altered gene expression associated with distinct genomic aberrations such as nucleophosmin (NPM1) mutations. To shed further light on the role of deregulated microRNA and gene expression in cytogenetically normal acute myeloid leukemia with NPM1 mutation we performed an integrative analysis of microRNA and mRNA expression data sets.
Both microRNA and gene expression profiles were investigated in samples from a cohort of adult cytogenetically normal acute myeloid leukemia patients (n=43; median age 46 years, range 23-60 years) with known NPM1 mutation status (n=23 mutated, n=20 wild-type) and the data were integratively analyzed. Putative microRNA-mRNA interactions were validated by quantitative reverse transcriptase polymerase chain reaction, western blotting and luciferase reporter assays. For selected microRNAs, sensitivity of microRNA-overexpressing cells to cytarabine treatment was tested by FACS viability and cell proliferation assays.
Our integrative approach of analyzing both microRNA- and gene expression profiles in parallel resulted in a refined list of putative target genes affected by NPM1 mutation-associated microRNA deregulation. Of 177 putative microRNA - target mRNA interactions we identified and validated 77 novel candidates with known or potential involvement in leukemogenesis, such as IRF2-miR-20a, KIT-miR-20a and MN1-miR-15a. Furthermore, our data showed that deregulated expression of tumor suppressor microRNAs, such as miR-29a and miR-30c, might contribute to sensitivity to cytarabine, which is observed in NPM1 mutated acute myeloid leukemia.
Overall, our observations highlight that integrative data analysis approaches can improve insights into leukemia biology, and lead to the identification of novel microRNA - target gene interactions of potential relevance for acute myeloid leukemia treatment.
microRNAs 是基因表达的调控因子,主要通过降低多个靶标 mRNA 的水平来发挥作用。已经发现急性髓系白血病(AML)中存在 microRNA 表达失调,该疾病还具有与特定基因组异常相关的改变基因表达的特征,例如核磷蛋白(NPM1)突变。为了进一步阐明在具有 NPM1 突变的细胞遗传学正常的急性髓系白血病中失调的 microRNA 和基因表达的作用,我们对 microRNA 和 mRNA 表达数据集进行了综合分析。
对一组已知 NPM1 突变状态的成人细胞遗传学正常 AML 患者(n=43;中位年龄 46 岁,范围 23-60 岁)的样本进行了 microRNA 和基因表达谱的调查,并进行了综合分析(n=23 例突变,n=20 例野生型)。通过定量逆转录聚合酶链反应、Western 印迹和荧光素酶报告基因测定验证推定的 microRNA-mRNA 相互作用。针对选定的 microRNAs,通过 FACS 活力和细胞增殖测定测试过表达 microRNA 的细胞对阿糖胞苷治疗的敏感性。
我们通过平行分析 microRNA 和基因表达谱的综合方法,得到了一个经过改良的、受 NPM1 突变相关 microRNA 失调影响的假定靶基因列表。在我们鉴定和验证的 177 个假定的 microRNA-mRNA 相互作用中,有 77 个是新的候选物,它们具有已知或潜在的参与白血病发生的作用,如 IRF2-miR-20a、KIT-miR-20a 和 MN1-miR-15a。此外,我们的数据表明,肿瘤抑制 microRNAs(如 miR-29a 和 miR-30c)的失调表达可能导致 NPM1 突变的急性髓系白血病对阿糖胞苷的敏感性增加。
总的来说,我们的观察结果强调了综合数据分析方法可以提高对白血病生物学的认识,并导致鉴定出潜在与急性髓系白血病治疗相关的新的 microRNA-靶基因相互作用。